ALTERATION OF NOREPINEPHRINE RESPONSES IN DOG BY DUAL ADRENERGIC BLOCKADE

被引:2
作者
NASH, CB
SMITH, RD
机构
[1] Department of Pharmacology, University of Tennessee Medical Units, Memphis, TN 38103
关键词
Blood lactic acid; Cardiac arrhythmias; hypotension; Myocardial hemorrhage; Norepinephrine post-infusional; Phenoxybenzamine; Propranolol; Serum potassium;
D O I
10.1016/0014-2999(69)90040-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Norepinephrine was infused into anesthetized dogs at a rate of 10 μg/kg/min for 2 hr and the animals sacrificed after an additional 2 hr. Measurements were made in the presence and absences of alpha blockade (phenoxybenzamine, 7.5 mg/kg), beta blockade (propranolol, 2 mg/kg), and dual adrenergic blockade (phenoxybenzamine, 7.5 + propranolol, 2 mg/kg). At these dose levels beta blockade alone did not prevent the decrease in blood pH; the increase in hematocrit, serum potassium, serum phosphorus, and blood lactic aicd; or the production of pericardil effusion, cardiac hemorrhage, cardiac arrhythmias and ECG voltage depression. Alpha blockade alone blocked hematocrit, serum phosphoruus, pericardial effusion effects and deaths, and reversed the rise in serum potassium. Dual blockade was unique in eliminating cardiac arrhythmias, decrease in blood pH, changes in serum potassium, rise in blood lactate, and largely reducing blood pressure changes. These data support the concept that certain effects of catecholamines are mediated by a combination of alpha plus beta stimulation. © 1969.
引用
收藏
页码:310 / &
相关论文
共 14 条
[1]  
AHLQUIST RP, 1959, J PHARMACOL EXP THER, V127, P146
[2]  
BREWER G, 1938, AM J PHYSIOL, V126, P708
[3]   PHEOCHROMOCYTOMA - TREATMENT WITH ALPHA- AND BETA-ADRENERGIC BLOCKING DRUGS [J].
CRAGO, RM ;
ECKHOLDT, JW ;
WISWELL, JG .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1967, 202 (09) :870-+
[4]  
ELLIS S, 1956, PHARMACOL REV, V8, P486
[5]   QUANTITATIVE BESTIMMUNG VON L(+)-MILCHSAURE MIT MILCHSAUREDEHYDROGENASE [J].
HORN, HD ;
BRUNS, FH .
BIOCHIMICA ET BIOPHYSICA ACTA, 1956, 21 (02) :378-380
[6]  
LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8
[7]  
MAYER S, 1961, J PHARMACOL EXP THER, V134, P18
[8]  
MORRIS RE, 1966, B NEW YORK ACAD MED, V42, P1007
[9]  
MUIRHEAD EE, 1954, AM J PHYSIOL, V179, P1
[10]  
NASH CB, 1968, J PHARMACOL EXP THER, V162, P246